Filing Details

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

SCHEDULE 13D

(Amendment No. 1)

(Rule 13d-101)

 

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

RULE 13d-2(a)

 

INMUNE BIO INC.

(Name of Issuer)

  

COMMON STOCK, PAR VALUE $0.001 PER SHARE

(Title of Class of Securities)

   

45782T 105

(CUSIP Number)

Mark Lowdell INmune Bio Inc. 1200 Prospect Street, Suite 525 La Jolla, CA 92037 (858) 964-3720

With Copies To:

Thomas Rose, Esq. Sichenzia Ross Ference LLP 1185 Avenue of the Americas, 37th floor New York, New York 10036 Tel: (212) 930-9700 Fax: (212) 930-9725

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

February 14, 2020

(Date of Event Which Requires Filing of This Statement)

   

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box ☐.

 

Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

(Continued on following pages)

 

 

  

CUSIP No. 45782T 105

13D

 

1	NAME OF REPORTING PERSONS S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS   Mark Lowdell
2	CHECK THE APPROPRIATE BOX IF MEMBER OF A GROUP   (a) ☐ (b) ☐ Reporting person is affiliated with other persons
3	SEC USE ONLY
4	SOURCE OF FUNDS   OO PF
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)   ☐
6	CITIZENSHIP OR PLACE OF ORGANIZATION   United Kingdom

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER   1,926,251 (1)
	8	SHARED VOTING POWER
	9	SOLE DISPOSITIVE POWER   1,926,251 (1)
	10	SHARED DISPOSITIVE POWER

11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON    1,926,251 (1)
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES    ☐
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)    17.25%*
14	TYPE OF REPORTING PERSON    IN

 

* Represents the percentage ownership based on 10,746,948 shares of common stock of INmune Bio Inc., Inc. outstanding as of February 10, 2020.

 

(1) Includes (i) 1,506,251 shares of common stock and (ii) 420,000 shares of common stock underlying options which have vested or will vest within sixty (60) days of this Schedule 13D

  

 

Item 1. Security and Issuer

 

This Schedule 13D relates to the Common Stock, par value $0.001 per share (the “Common Stock”) of INmune Bio Inc., a Nevada corporation (the “Issuer”), whose principal executive offices are located at 1200 Prospect Street, Suite 525, Suite 150 La Jolla, California 92037.

 

Item 2. Identity and Background.

 

(a)

Mark Lowdell, an individual (the “Reporting Person”).

 

(b)

The business address of the Reporting Person is INmune Bio Inc., a Nevada corporation (the “Issuer”), whose principal executive offices are located at 1200 Prospect Street, Suite 525, Suite 150 La Jolla, California 92037.

 

(c)

Reporting Person is the Chief Scientific Officer of the Issuer.

 

(d)

Reporting Person has not, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

 

(e)

Reporting Person has not, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws.

 

(f)

Reporting person is a citizen of the United Kingdom.

 

Item 3. Source and Amount of Funds or Other Consideration.

 

On February 1, 2019 the Company sold 1,020,820 shares of its of common stock in an initial public offering at $8.00 per share and listed its shares of common stock on the Nasdaq Capital Market. As of the date of the Company’s initial public offering (the “IPO”), the Reporting Person beneficially owned 1,753,323 shares of the Company’s common stock , of which (i) 1,503,333 shares were owned by the Reporting Person prior to the Company’s IPO and were acquired by the Reporting Person during the Company’s incorporation at a purchase price of $0.002 per share, and (ii) 400,000 shares may be acquired pursuant to the exercise of stock options (the “Original Options”) granted to the Reporting Person by the Company (249,990 shares of common stock underlying options were vested within 60 days of February 1, 2019). Subsequently, the Reporting Person (i) was granted options to purchase 180,000 shares of the Company’s common stock (the “Subsequent Options” and together with the Original Options the “Options”) and (ii) purchased 2,918 shares of common stock in a previously disclosed open market transaction. Any funds used to purchase securities from the Company were personal funds. Of the amount of Options granted to the Reporting Person, Options to purchase 410,000 are currently vested and the remaining balance vests at a rate of 5,000 shares a month.

 

 

Item 4. Purpose of Transaction.

 

The information furnished in Item 3 is incorporated into this Item 4 by reference.

 

Item 5. Interest in Securities of the Issuer.

 

(a)

As of the date hereof, the Reporting Person beneficially owns 1,926,251 shares of the Issuer’s common stock, which represents approximately 17.25% of the Issuer’s common stock.

 

(b)

The Reporting Person may be deemed to hold sole voting and dispositive power over his 1,926,251shares of common stock of the Issuer.

 

(c)

Other than the acquisition of the shares as reported herein, and as described under Item 4, the Reporting Person has not effected any transactions in the shares of the Issuer during the past 60 days or since the most recent filing of Schedule 13D, whichever is less.

 

(d)

To the best knowledge of the Reporting Person, no person other than the Reporting Person has the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of the 1,926,251 shares of common stock reported in Item 5(a).

 

(e)

Not applicable.

 

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

 

There are no contracts, agreements, understandings or relationships (legal or otherwise) between the Reporting Person and any other person with respect to any securities of the Issuer. 

 

Item 7. Material to be Filed as Exhibits.

 

None.

 

 

SIGNATURES

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and accurate.

 

	Mark Lowdell
February 14, 2020	By:	/s/ Mark Lowdell
		Name: Mark Lowdell

 

 

5